Spirovant Sciences
Phase 1/2Spirovant is a gene therapy company developing treatments and cures for respiratory diseases including cystic fibrosis.
Founded
2018
Focus
RNA & Gene Therapy
About
Spirovant is a gene therapy company developing treatments and cures for respiratory diseases including cystic fibrosis.
Funding History
2Total raised: $260M
Series B$150MFidelity Management & Research CompanySep 15, 2021
Series A$110MBain Capital Life SciencesDec 15, 2019
Company Info
TypePrivate
Founded2018
LocationPhiladelphia, United States
StagePhase 1/2
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile